Hangzhou Sumgen Biotech Co., Ltd.
Clinical trials sponsored by Hangzhou Sumgen Biotech Co., Ltd., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug targets Hard-to-Treat cancers by homing in on a specific protein Results expected Feb 2027 (estimated)
- Can a new infusion stop the Body's attack on a transplanted kidney? Results expected Mar 2027 (estimated)
- New antibody combo aims to stall multiple Myeloma's return Results expected Mar 2027 (estimated)
- Experimental injection aims to boost platelets in chronic blood disorder Results expected May 2027 (estimated)
-
New drug SG1827 enters first human tests for Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tests a new drug, SG1827, in people with advanced solid tumors that have stopped responding to standard treatments or have no standard therapy available. The main goals are to check the drug's safety, find the best dose, and get a first look at whether it c…
Phase 1 • Sponsor: Hangzhou Sumgen Biotech Co., Ltd. • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New cancer drug SG2918 enters first human tests
Disease control CompletedThis early-stage trial tests an experimental drug called SG2918 in 17 people with advanced cancers that no longer respond to standard treatments. The main goal is to check safety and find the right dose, not yet to prove it works. Participants receive the drug by IV every three w…
Phase 1 • Sponsor: Hangzhou Sumgen Biotech Co., Ltd. • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New lupus injection enters first human tests
Disease control CompletedThis early-stage trial tests a new drug called SG301, given as an injection under the skin every two weeks, for systemic lupus erythematosus (SLE). The study first gives a single dose to healthy volunteers to check safety, then gives multiple doses to people with lupus. The main …
Phase 1 • Sponsor: Hangzhou Sumgen Biotech Co., Ltd. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC